• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
180824 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
; X. Z6 Y  Z% n4 w1 D) M
5 X1 A0 C6 ?1 r  B2 J3 I- P% r7 h
. g3 x( E! B" hSub-category:
/ c; x# Y1 a; v( Z0 tMolecular Targets 7 q( r' d* s: ~/ I" j9 w. E

6 Q: _) |$ [; ], i, r/ F
6 c4 y* ]8 y/ a" gCategory:
9 @9 L, W+ \* M& t6 B1 MTumor Biology
6 H: x4 z7 I  S2 V9 \2 y! Q0 e" T( j4 w0 k8 H
: Y2 C9 f& I+ f/ ?9 b4 a8 Q8 r
Meeting:
5 d  D$ p0 o5 m, r; o( Z2011 ASCO Annual Meeting ; b0 F! b! G' S

) [  I' D! a( C6 J) n- R) ~: w. s6 f4 f% m: D8 W2 t7 p! j! H
Session Type and Session Title:/ d0 m" ?5 B% x/ b3 [1 c
Poster Discussion Session, Tumor Biology
/ Y+ P6 V7 ^4 W; i3 ~  s3 K( k# }2 {! D' k$ v
, C8 j7 C/ n" p) Y' B# \9 Q& x
Abstract No:& w/ F6 F+ [1 P  o  ]# F/ Q1 }
10517 - r  E5 {; p8 g& ~' O+ Q9 a
4 V. o- H5 [% ?$ [

& M, n% F+ i4 U( _Citation:( u6 S/ c. {$ k+ m+ I; m- n& c( k
J Clin Oncol 29: 2011 (suppl; abstr 10517) ; S+ m: C& O1 s7 T% j% [

; B. _# P6 Q" [* \" u3 \, A. C( N, h
Author(s):7 C/ Y5 E: H* M6 b( P: E
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 3 U0 o% e! c0 X- b
4 p2 A4 }- m) N" }

, l8 `# \+ n9 `- n8 Z+ K+ F
9 z! I  S* e" @/ X1 G& O8 AAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.- L- {7 F$ m# m! F6 u

6 E; V; [2 H# a2 WAbstract Disclosures
5 K& \( V# Q" W3 a$ s# C
) g+ ]: d; G/ g4 ?; L% wAbstract:3 O) a4 ~' A( o  k4 T! P4 W

; ^- `/ d8 }/ F2 U5 H# M
! k% N4 e0 _8 {/ _Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.3 \5 ^# {: S5 m) [, W! @( V
! y1 U: m9 w8 k6 Y% Y

- N# J% |+ M5 v
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
* Y, P& V6 t: z1 x' q, Y没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
4 p1 x& p3 e! y$ D* b* \" V
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 - H+ l) F; Q9 c1 j0 S) M1 s5 \# I
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。$ }4 x+ W$ O: Q& }! J
ALK一个指标医院要900多 ...

# Z6 W- k3 H  M平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?; w& [7 c$ W% o& K
4 ~$ i$ V" u6 h
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表